![Linda Sjöström](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Linda Sjöström
Private Equity Investor bei
Bankinvest Private Equity A/S
Profil
Linda Sjöström joined BankInvest Biomedical Venture team as Partner in early 2001.
She focuses on investments within drug discovery and drug development.
Mrs. Sjöström has been an active member of the venture capital community for more than 14 years, working with life science and biotechnology for Danish Venture Finance A/S and now BankInvest.
Before that she worked more than 17 years in the pharmaceutical industry.
Prior positions include Managing Director of the Danish subsidiary of Syntex Inc. (now bought by Roche) and other positions with Schering, Ciba-Geigy (now Novartis) and Rhône-Poulenc (now Aventis).
Mrs. Sjöström holds a master's degree in Chemical Engineering with an emphasis on Biochemistry.
Aktive Positionen von Linda Sjöström
| Unternehmen | Position | Beginn |
|---|---|---|
Bankinvest Private Equity A/S
 Bankinvest Private Equity A/S Investment ManagersFinance Acts as an alternative investment manager | Private Equity Investor | - |
Ehemalige bekannte Positionen von Linda Sjöström
| Unternehmen | Position | Ende |
|---|---|---|
Meabco A/S
 Meabco A/S Pharmaceuticals: MajorHealth Technology Develops and sells cancer therapy products | Direktor/Vorstandsmitglied | 17.04.2021 |
BioStratum, Inc.
 BioStratum, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Direktor/Vorstandsmitglied | 05.07.2011 |
BI Technology A/S
 BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Private Equity Investor | 01.02.2009 |
| ZEALAND PHARMA A/S | Direktor/Vorstandsmitglied | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
8
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
BioStratum, Inc.
BioStratum, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Finance |
ACE BioSciences ApS
 ACE BioSciences ApS Pharmaceuticals: MajorHealth Technology Discovers and develops novel vaccines for the prevention and treatment of bacterial infections | Health Technology |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
Meabco A/S
Meabco A/S Pharmaceuticals: MajorHealth Technology Develops and sells cancer therapy products | Health Technology |
Bankinvest Private Equity A/S
Bankinvest Private Equity A/S Investment ManagersFinance Acts as an alternative investment manager | Finance |
